Related references
Note: Only part of the references are listed.Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Erik Tambuyzer et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Soluble ligands as drug targets
Misty M. Attwood et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Estimation of clinical trial success rates and related parameters
Chi Heem Wong et al.
BIOSTATISTICS (2019)
Trends in clinical success rates and therapeutic focus
Helen Dowden et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Hsin-Pei Shih et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
A comprehensive map of molecular drug targets
Rita Santos et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Trends in GPCR drug discovery: new agents, targets and indications
Alexander S. Hauser et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Innovation in the pharmaceutical industry: New estimates of R&D costs
Joseph A. DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2016)
FROM THE ANALYST'S COUCH Trends in clinical success rates
Katarzyna Smietana et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
The support of human genetic evidence for approved drug indications
Matthew R. Nelson et al.
NATURE GENETICS (2015)
Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
David Cook et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Clinical Approval Success Rates for Investigational Cancer Drugs
J. A. DiMasi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Does size matter in R&D productivity? If not, what does?
Michael Ringel et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
Paul Morgan et al.
DRUG DISCOVERY TODAY (2012)
Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
The productivity crisis in pharmaceutical R&D
Fabio Pammolli et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
J. A. DiMasi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Averting inflammation by targeting the cytokine environment
Manfred Kopf et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Do molecularly targeted agents in oncology have reduced attrition rates?
Ian Walker et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Opinion - Drugs, their targets and the nature and number of drug targets
Peter Imming et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Monoclonal antibody successes in the clinic
JM Reichert et al.
NATURE BIOTECHNOLOGY (2005)
Share Paper
